{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Antibody Drug Conjugates: New Weapons Against Cancer
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide information on antibody drug conjugates (ADCs) that have been approved by the Food & Drug Administration (FDA).Learning Objectives
After completing this continuing education activity you will be able to:
- Evaluate the use of antibody drug conjugates (ADCs) for patients with advanced/metastatic disease.
- Describe the indications for those ADCs that are currently available.
Disclosures
The author(s), faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational actitivity.
Price:
$12.95
Credits:
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0320
Published: March 2020
Expires: 1/1/2026
Sources:
Oncology Times
Required Passing Score: 8/10 (80%)
Specialties:
Oncology